Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research note issued to investors on Monday morning.

A number of other research analysts have also recently weighed in on COLL. HC Wainwright raised shares of Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 price target on the stock in a research report on Tuesday, July 30th. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a hold rating to a buy rating and lifted their price target for the company from $41.00 to $44.00 in a research report on Friday, June 7th. Piper Sandler reiterated a neutral rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Truist Financial lifted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a buy rating in a research note on Friday, August 9th. Finally, Needham & Company LLC reiterated a hold rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $42.00.

Collegium Pharmaceutical Price Performance

COLL opened at $34.30 on Monday. The company’s 50 day simple moving average is $33.27 and its 200 day simple moving average is $34.89. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $40.95. The stock has a market capitalization of $1.12 billion, a PE ratio of 14.29 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. Collegium Pharmaceutical’s revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.13 earnings per share. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 5.73 EPS for the current year.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at $3,598,549.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of COLL. Gladius Capital Management LP acquired a new position in shares of Collegium Pharmaceutical during the second quarter valued at $32,000. Principal Securities Inc. acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $40,000. nVerses Capital LLC boosted its holdings in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares during the period. Assetmark Inc. boosted its holdings in shares of Collegium Pharmaceutical by 25.5% during the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares during the period. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in Collegium Pharmaceutical in the first quarter worth about $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.